title: Comparative study of incadronate and elcatonin in patients with malignancy-associated hypercalcaemia.
abstract: The clinical usefulness of incadronate was compared with elcatonin in 26 patients with malignancy-associated hypercalcaemia. Data from 21 and 24 patients could be used to assess efficacy and safety, respectively. Eleven patients were given a single 10-mg intravenous infusion of incadronate and 10 received twice-daily intramuscular injections of 40 IU of elcatonin for 7 consecutive days. After treatment, corrected serum calcium levels decreased significantly in both groups. The anti-hypercalcaemic effect of elcatonin was characterized by its rapid onset, with serum calcium levels reduced 1 day after administration. In contrast, the anti-hypercalcaemic effect of incadronate was more sustained but only became apparent a few days after infusion. Evaluation of symptoms revealed significantly greater improvement rates in the incadronate group compared with the elcatonin group. Adverse drug reactions were observed in three patients in the incadronate group, i.e. mild and transient fever in two cases and exacerbation of disturbance of consciousness in one case. These findings suggest that incadronate produces more marked and sustained hypocalcaemic effects than elcatonin, and that co-administration of these two drugs may yield both rapid and sustained control of malignancy-associated hypercalcaemia.
authors.affiliation: First Department of Internal Medicine, School of Medicine, University of Tokushima, Tokushima, Japan. toshimat@clin.med.tokushima-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Matsumoto
authors.forename: N
authors.initials: N
authors.lastname: Nagata
authors.forename: N
authors.initials: N
authors.lastname: Horikoshi
authors.forename: I
authors.initials: I
authors.lastname: Adachi
authors.forename: Y
authors.initials: Y
authors.lastname: Ohashi
authors.forename: E
authors.initials: E
authors.lastname: Ogata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications*
chemical_list: D004164:Diphosphonates; C071542:cimadronate; D002116:Calcitonin; C012755:elcatonin